This article first appeared on GuruFocus .
Release Date: November 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Supriya Lifescience Ltd ( BOM:543434 ) achieved a 20% year-on-year sales growth in Q2 FY26, reflecting strong recovery and operational resilience.
-
The company reported a significant improvement in EBITDA, which stood at INR 73 crores, up 12% year-on-year, with a robust EBITDA margin of 36%.
-
Exports accounted for 81% of the company's Q2 FY26 revenues, highlighting its strong international market presence.
-
The company is making substantial progress in backward integration, with 79% of FY26 revenues now fully integrated, enhancing operational efficiency.
-
Supriya Lifescience Ltd ( BOM:543434 ) is on track to achieve its long-term revenue target of INR 1,000 crore by FY27, supported by a healthy product pipeline and strategic market expansion.
Negative Points
-
The company's H1 FY26 revenue growth was only 6% year-on-year, indicating a slow start to the fiscal year due to earlier operational challenges.
-
There were delays in the DSM project, with full revenue potential expected only in FY27, impacting short-term financial performance.
-
The North American market remains a small contributor to overall revenues, with challenges in scaling up product approvals and market penetration.
-
The company faces ongoing regulatory hurdles, which could delay the commercialization of new products and impact revenue growth.
-
Despite achieving strong margins, the company maintains a conservative margin guidance of 33-35%, indicating limited room for margin expansion in the near term.
Q & A Highlights
-
Warning! GuruFocus has detected 4 Warning Signs with BOM:543434.
-
Is BOM:543434 fairly valued? Test your thesis with our free DCF calculator.
Q: Given the 6% revenue growth in H1 FY26, do you still see achieving the 20% revenue growth target for the year? What are the key growth levers for the second half? A: We are confident in achieving our 20%+ revenue growth target. The muted start in Q1 was due to essential debottlenecking activities. We expect full recovery in Q3 and Q4, driven by growth in our existing product portfolio, new product launches, and CMO/CDMO opportunities.
Q: Can you provide more details on the CDMO business and the DSM project? A: The DSM opportunity is expected to generate INR 60-70 crores at full peak, with INR 25-30 crores expected this year. We have other projects in the pipeline, and the Amberna facility is ready for commercialization, with revenue expected from semi-regulated markets initially.
Q: What is the status of the API segment, particularly the anesthetic drug launched last quarter? A: We have not yet filed for the CEP and US DMF due to process fine-tuning and scaling up batch sizes. We plan to complete these filings by the end of November. The product has no competitors in India, and there is significant interest from clients looking to shift from non-GMP Chinese sources.
Q: What are the expectations for the whey protein contract, and when can we see volume ramp-up? A: We are working with the end customer on formulation changes. We expect commercial supply to start soon, with full potential likely realized in FY28. Our capacity is set up for 3,000 tons annually, with initial volumes expected to be around 1,000 tons in FY27.
Q: How are the new product launches progressing, and what are the plans for the cardiovascular intermediate and contrast media products? A: We have launched two products so far, with filings expected by the end of November. The cardiovascular intermediate has a capacity of 1,000 tons, with 300 tons already in advanced discussions. The contrast media product is in pilot scale validation, with more details to be shared after Q3.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
